BR9814830A - Desire reduction method in mammals - Google Patents

Desire reduction method in mammals

Info

Publication number
BR9814830A
BR9814830A BR9814830-3A BR9814830A BR9814830A BR 9814830 A BR9814830 A BR 9814830A BR 9814830 A BR9814830 A BR 9814830A BR 9814830 A BR9814830 A BR 9814830A
Authority
BR
Brazil
Prior art keywords
mammals
desire
reduction method
mammal
desire reduction
Prior art date
Application number
BR9814830-3A
Other languages
Portuguese (pt)
Inventor
Vicki Coffin
Paul W Glue
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9814830A publication Critical patent/BR9814830A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"MéTODO DE REDUçãO DE DESEJO EM MAMìFEROS"<D>. é revelado um método de redução de desejo em um mamífero por comida ou por uma substância viciadora. O método compreende a administração ao mamífero de uma quantidade eficaz de um antagonista de D~ 1~/D~ 5~ ou de um agonista parcial de D~ 1~/D~ 5~ sozinho ou em combinação com outros compostos de CNS especificados.Invention Patent: <B> "METHOD OF REDUCING DESIRE IN MAMMALS" <D>. a method of reducing a mammal's desire for food or an addictive substance is revealed. The method comprises administering to the mammal an effective amount of a D ~ 1 ~ / D ~ 5 ~ antagonist or a partial D ~ 1 ~ / D ~ 5 ~ agonist alone or in combination with other specified CNS compounds.

BR9814830-3A 1997-10-28 1998-10-26 Desire reduction method in mammals BR9814830A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28
PCT/US1998/022255 WO1999021540A2 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals

Publications (1)

Publication Number Publication Date
BR9814830A true BR9814830A (en) 2000-10-03

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814830-3A BR9814830A (en) 1997-10-28 1998-10-26 Desire reduction method in mammals

Country Status (16)

Country Link
EP (1) EP1043980A2 (en)
JP (1) JP2001520989A (en)
KR (1) KR20010031470A (en)
CN (1) CN1283116A (en)
AR (1) AR015984A1 (en)
AU (1) AU1110099A (en)
BR (1) BR9814830A (en)
CA (1) CA2308453A1 (en)
CO (1) CO4970824A1 (en)
HU (1) HUP0100115A2 (en)
IL (1) IL135659A0 (en)
NO (1) NO20002149L (en)
PE (1) PE122299A1 (en)
SK (1) SK5812000A3 (en)
WO (1) WO1999021540A2 (en)
ZA (1) ZA989786B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908392A (en) * 1998-03-02 2000-10-31 Schering Corp Use of d1 / d5 antagonists for the treatment of obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders and autism
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
EP1441708B1 (en) 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
WO2012050594A1 (en) 2010-09-01 2012-04-19 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
PL2872145T3 (en) 2012-07-12 2022-06-20 Emalex Biosciences, Inc. Fused benzazepines for treatment of tourette's syndrome
LT3057595T (en) 2013-10-18 2020-08-10 Emalex Biosciences, Inc. Fused benzazepines for treatment of stuttering
CN110327350B (en) * 2019-07-11 2021-02-23 温州医科大学 Application of dopamine D1 receptor antagonist SCH39166 as a drug for the treatment of ocular pathological angiogenesis
CN110833621A (en) * 2019-12-06 2020-02-25 中国医科大学 Application of dopamine receptor 1 antagonists in the preparation of drugs for the treatment of schizophrenia-like mice induced by ketamine
US12594281B2 (en) 2024-03-15 2026-04-07 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU3408097A (en) * 1996-06-06 1998-01-05 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Also Published As

Publication number Publication date
SK5812000A3 (en) 2000-12-11
JP2001520989A (en) 2001-11-06
CO4970824A1 (en) 2000-11-07
CA2308453A1 (en) 1999-05-06
WO1999021540A3 (en) 1999-09-02
IL135659A0 (en) 2001-05-20
WO1999021540B1 (en) 1999-10-28
EP1043980A2 (en) 2000-10-18
NO20002149D0 (en) 2000-04-27
AU1110099A (en) 1999-05-17
CN1283116A (en) 2001-02-07
HUP0100115A2 (en) 2001-06-28
ZA989786B (en) 1999-04-28
KR20010031470A (en) 2001-04-16
AR015984A1 (en) 2001-05-30
PE122299A1 (en) 1999-12-04
NO20002149L (en) 2000-06-26
WO1999021540A2 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
BR9814830A (en) Desire reduction method in mammals
NO980729D0 (en) Procedure for reducing the acid content of crude oil
NO961223L (en) Increased corrosion protection when using friction reducing agents in connection with corrosion inhibitors
EE200100243A (en) 5HT1 receptor agonists and metoclopramide for the treatment of migraine
DE69434891D1 (en) Use of NMDA antagonists for the treatment of pain
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
BR9910180A (en) Pharmaceutical composition, processes for the treatment of a condition associated with reduced nicotine transmission, for the identification of a positive modulator of a nicotinic receptor agonist and for the identification of a compound, compound, and use of a positive modulator of a nicotinic receptor agonist
DE69912279D1 (en) 5-HT1F AGONISTS
NZ505193A (en) Opioid agonist/antagonist combinations
BR9807577A (en) Method to prevent and delay the onset of Alzheimer&#39;s disease and its composition
BR9908598A (en) 20-keto-11beta-arylsteroids and their derivatives having agonistic or antagonistic hormonal properties
PL315653A1 (en) Application of 4-chloro-5-(imidazolyn-2-ylamino)-6-methoxy-2-methylpyrimidine and i1 agonist as pharmaceutic agents and pharmaceutic agent as such
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer&#39;s disease
KR870003974A (en) Bicyclo substituted phenylacetonitrile derivatives
NZ333723A (en) A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor
NO960192L (en) Mineral Fiber Blend
BR0113321A (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin converting enzyme inhibitors i
BR9712283A (en) Method for inhibiting tension-activated protein kinases
AU5146096A (en) Compositions for treatment of photodamaged skin comprising a n rar-alpha antagonist and a multi-selective retinoid
WO1999024023A3 (en) FORMULATION OF A COMBINATION COMPRISED OF OPIOID AND α - ADRENERGIC AGONISTS AND THE APPLICATION THEREOF
ID22060A (en) COMPOUNDS OF 2-IMIDAZOLINYLAMINOBENZOKSAZOL USE AS ADRENOSEPTOR AGONISTS
BG105277A (en) Prevention of migraine recurrence
CA2322229A1 (en) Compositions comprising heparin and soluble tnf receptors for inhibition of tnf activity
BR0215064A (en) Selective d3 dopamine receptor agonists for the treatment of sexual dysfunction
SG77214A1 (en) Compositions for the reduction of scarring

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]